Satyen Gohil
@satyengohil
Consultant Haematologist UCLH & UCL. Interested in Lymphoma, CAR-T, CLL, Histiocytic Disorders & HLH
ID: 306121345
27-05-2011 09:54:40
336 Tweet
609 Followers
700 Following
Who wants to come and join Dr francesca kinsella and I for what promises to be an exciting, NIHR Birmingham Biomedical Research Centre National Institute for Health and Care Research funded 3 year #Phd? All about cellular therapies and infection 🤩👇. birmingham.ac.uk/study/postgrad…. Institute Immunology and Immunotherapy.
Brilliantly supervised by Sara Ghorashian and amazing insights thanks to Nathaniel D Anderson. These long lived CAR T cells are extremely unique and very specific, first step in understanding their longevity and functional state. #CART.
Catching up with Kanti Rai, one of the giants of #CLL in Boston Piers Patten, Sunil Iyengar, Peter Hillmen, Nicholas Chiorazzi, Andy Rawstron #iwCLL2023 @UkCll
If you are a Cancer Researcher interested in preclinical mechanistic studies to target the tumour-microenvironment and are looking for an Assistant-position, please apply. This project is funded for 5 years through a Dung Nguyen Discovery Programme Award ucl.ac.uk/work-at-ucl/se…
Looks great Ingo Ringshausen
Thanks to Science and Innovation at Cancer Research UK for the funding and looking forward to working with such a great team
CAR-T Fellow post available UCLH. Application deadline 04/06/2025. Working with the fabulous Claire Roddie Maeve O'Reilly Paul Maciocia Mike Northend uclh.nhs.uk/work-with-us/c…
Check out how CD19CAR-T for Richters Transformation stacks up in this UK analysis. Broadly safe and effective, ORR 70%, 2y PFS 46%. Risks for poor response- high LDH, non-response bridging, more prior lines. UCL Cancer Institute Satyen Gohil onlinelibrary.wiley.com/doi/10.1111/bj…